NRX Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of common stock and warrants, with gross proceeds expected to be approximately $6.28 million, to be used for research into the use of NRX-101 for the treatment of PTSD and Chronic Pain.